средняя общеобразовательная школа 11 города костромы
Главное меню:
Интересное
средняя общеобразовательная школа 11 города костромы, Clinical Trials for Ulcerative Colitis - NIDDK, Ulcerative Colitis in Adults – Guidelines+ Trials Rundown, Clinical Studies, Trial Design & Data | UC | Omvoh , Ulcerative colitis clinical trials: Research and more, Mirikizumab Administered at the Same Time as Tirzepatide in , , .
Primary Outcomes Measures: Induction Study 1: Percentage of Participants With Clinical Response at Week I-12, Clinical response was defined as a decrease from induction baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1 point decrease from baseline (Week 0 of IS-1) in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only., At Week I-12|Induction Study 2: Percentage of Participants With Clinical Remission at Week I-12, Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only., At Week I-12|Maintenance Study: Percentage of Participants With Clinical Remission at Week M-44, Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-1 and IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for randomized arms only., At Week M-44, Read about clinical trials for ulcerative colitis. Clinical trials are at the heart of all medical advances. Find out if clinical trials are right for you., This article takes a look at the ongoing studies and clinical trials specific to Ulcerative Colitis (UC) in Adults..
Find Omvoh efficacy data for Ulcerative Colitis, including clinical remission and other endpoints from pivotal trials., People with ulcerative colitis may be able to participate in clinical trials to test the effectiveness and safety of new treatments for the condition. Learn more here., Clinical Trial Resources Crohn's + Ulcerative Colitis Research To learn more about Crohn's and ulcerative colitis and ongoing clinical trials in this area, visit our Crohn's + Ulcerative Colitis Research page., , , .